SPCG-3

Cancelled trial due to Socialstyrelsen in Sweden

Cancelled trial due to Socialstyrelsen in Sweden.

Stopped before inclusion

SPCG-3 info

Principal investigator

Lars Collsten and Per Olov Hedlund

Contact details

Patients

T3,N0,M0

Treatment

Radical prostatectomy plus/minus chemotherapy

Inclusion period

Never started – deleted by Socialstyrelsen, Sweden

More trials

Recruiting/Active

SPCG 19/ Get-Randomized- Prostate (Grand-P): A randomized, multi-center trial of immediate curative therapy compared with standard conservative treatment in older men aged ≥ 75 years with non-metastatic, high-risk prostate cancer

Recruiting/Active

Prostate Cancer Active Surveillance Trigger Trial (PCASTT)

Stopped before inclusion

No information available

Recruiting/Active

Primary radical prostatectomy versus primary radiotherapy for locally advanced prostate cancer: an open randomized clinical trial

Stopped inclusion/Active

SPCG-14 (SPCG-14 PSA-ERECT M0)

A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation ± Docetaxel for Non-metastastic Prostate Cancer Patients with a Rising PSA

A Randomized phase III trial of six cycles of docetaxel versus surveillance plus hormonal treatment after radical radiotherapy in patients with intermediate or high-risk prostate cancer (SPCG-13 AdRad)

An open randomised phase III trial of six cycles of docetaxel versus surveillance after radical prostatectomy in prostate cancer patients with high grade pT3 or margin positive pT2

Stopped before inclusion

Effectiveness of Zometa® treatment for the prevention of bone metastases in high risk prostate cancer patients. A randomized, open-label, multicenter study of the European Association of Urology (EAU) in cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO)

Randomised trial comparing radical prostatectomy versus radiotherapy plus protocol on follow-up of non-randomised patients with localised prostate cancer

Antiandrogen followed by TAB on biochemical progression versus TAB

An open pilot study evaluating intermittent androgen suppression in patients with advanced prostate cancer

Institution of second-line Estracyt therapy at an increase in PSA values for metastatic prostate cancer

SPCG-7 Biopsy study

Post-treatment Prostatic Biopsies after Antiandrogen treatment with or without Radiotherapy

Randomized trial of locally advanced prostate cancer. Antiandrogen treatment with or without radiotherapy

A randomized, double-blind, parallel-group trial comparing Casodex 150 mg once daily with placebo in patients with non-metastatic prostate cancer

High-dose Polyestradiol Phosphate versus Total Androgen Blockade

Expectation or radical prostatectomy on early prostate cancer

Finished nt-03 nt-04

Orchiectomy plus placebo versus orchiectomy plus cyproteronacetat

Comparison of Estramustine Phosphate to Stilbestrol in the treatment of G3 M Prostatic